Business Context and Reporting Period
Company: BioTime, Inc. (Note: Input metadata referenced Lineage Cell Therapeutics, but the filing text identifies BioTime, Inc.)
Reporting Period: Quarterly period ended September 30, 1998.
Status: Development stage company engaged in research and development of synthetic plasma expanders, blood volume substitute solutions, and organ preservation solutions.
Fiscal Change: The Company changed its fiscal year-end from June 30 to December 31, effective December 31, 1998.
Key Financial Metrics
| Metric | Three Months Ended Sept 30, 1998 | Three Months Ended Sept 30, 1997 | Cumulative from Inception (Nov 1990) to Sept 30, 1998 |
|---|---|---|---|
| Revenue | $125,000 | $125,000 | $1,337,500 (License fees) |
| Interest & Other Income | $48,129 | $76,145 | $1,261,363 |
| Total Expenses | $(1,310,871) | $(1,183,766) | $(18,348,632) |
| Net Loss | $(1,137,742) | $(982,621) | $(15,749,769) |
| Loss Per Share (Basic/Diluted) | $(0.11) | $(0.10) | N/A |
| Cash and Cash Equivalents (End of Period) | $3,303,000 | $7,370,991 | $3,303,000 |
| Net Cash Used in Operating Activities | $(1,176,873) | $(990,421) | $(14,783,176) |
| Net Cash Provided by Financing Activities | $375,390 | $580,840 | $18,265,042 |
| Total Assets | $3,764,725 | N/A | N/A |
| Total Liabilities | $449,827 | N/A | N/A |
| Shareholders' Equity | $3,314,898 | N/A | N/A |
Material Changes vs. Prior Period
- Revenue: License fee revenue remained flat at $125,000 compared to the prior year quarter. Interest income decreased to $48,129 from $76,145 due to lower cash balances.
- Expenses: Total expenses increased to $1,310,871 from $1,183,766. Research and Development (R&D) expenses rose to $930,418 from $678,272, driven by increased development and testing of the product "PentaLyte."
- General & Administrative (G&A): G&A expenses decreased to $380,453 from $505,494, primarily due to a reduction in personnel costs and bonuses accrued in the prior year.
- Liquidity: Cash and cash equivalents decreased by approximately $802,781 during the quarter, resulting in a balance of $3.3 million.
Guidance, Outlook, and Risks
- Regulatory Status: The Company submitted a New Drug Application (NDA) to the FDA on March 31, 1998, for its product "Hextend." Approval is not guaranteed, though Phase III clinical trial endpoints were met.
- Licensing Strategy: BioTime has an exclusive license agreement with Abbott Laboratories for Hextend in the U.S. and Canada. Abbott has paid $1.65 million in license fees to date, with up to $40 million potentially payable based on milestones and sales royalties (5% to 36%).
- Capital Needs: Management expects to incur losses for the foreseeable future. Additional financing will be required to complete product development and clinical trials. Future funding is expected to come from licensing fees, royalties, or equity/debt sales.
- Risks: Key risks include failure to obtain FDA or foreign regulatory approval, inability to secure additional financing, competition, and reliance on third-party contractors for data analysis and manufacturing.
- Year 2000: The Company does not expect material expenses for Year 2000 compliance but notes reliance on third-party suppliers and Abbott for manufacturing and data systems.
Investor Verification Checklist
- FDA Approval: Verify the status of the Hextend New Drug Application (NDA) submitted in March 1998.
- Liquidity Runway: Assess if the $3.3 million cash balance is sufficient to fund operations until the next anticipated milestone payment or financing event.
- Abbott Milestones: Confirm the specific milestones required to trigger the remaining $850,000 in license fees and the timeline for potential royalty payments.
- R&D Pipeline: Review the progress and cost estimates for the clinical trials of PentaLyte and HetaCool.
- Fiscal Year Change: Note the transition to a December 31 fiscal year-end and the resulting six-month 10-K filing for the period ending December 31, 1998.